# US 2020/0369734 A1 · Chimeric peptide for a biomimetic implant interface

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0369734 A1
- Document ID: US20200369734A1
- Status: Published application
- Kind: A1
- Application number: 16/640,662
- Filed: 2018-08-21
- Published: 2020-11-26
- Earliest claimed: 2017-08-21
- Assignees: University of Kansas
- Applicants: University of Kansas
- Inventors: Candan Tamerler-Behar; Emily Caitlyn Wisdom; Kyle Boone
- Web page: https://patentgrep.com/patent/US20200369734A1

## CPC

- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- C07K 14/47: from mammals
- A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)}
- C07K 14/4723: {Cationic antimicrobial peptides, e.g. defensins}
- C07K 17/14: Peptides being immobilised on, or in, an inorganic carrier
- C12N 15/62: DNA sequences coding for fusion proteins
- A61L 2300/252: Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
- A61L 2300/404: Biocides, antimicrobial agents, antiseptic agents
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2319/00: Fusion polypeptide
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/20: containing a tag with affinity for a non-protein ligand
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided in this disclosure are chimeric peptides that include a spacer domain, the spacer domain itself, substrates (e.g., implants) coated with the chimeric peptides, and methods for making and using the coated substrates.

## Claims

### Claim 1

A chimeric peptide comprising an inorganic binding domain having an amino acid sequence selected to bind to an inorganic surface, an antimicrobial domain having an amino acid sequence selected to exhibit antimicrobial activity, and a spacer domain between the inorganic binding domain and the antimicrobial domain, the spacer domain having an amino acid sequence engineered to retain the antimicrobial activity of the antimicrobial domain.

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The chimeric peptide of claim 1, wherein the spacer domain amino acid sequence is GSGGG (SEQ ID NO: 2).

### Claim 9 (depends on 1)

The chimeric peptide of claim 1, wherein the antimicrobial domain amino acid sequence exhibits antimicrobial activity against bacteria associated with clinic implant infections.

### Claim 10 (depends on 9)

The chimeric peptide of claim 9, wherein the bacteria comprise S. mutans, S. epidermidis, and combinations thereof.

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13 (depends on 1)

The chimeric peptide of claim 1, wherein the inorganic binding domain amino acid sequence is that of a titanium binding peptide, and the antimicrobial domain amino acid sequence is that of an antimicrobial domain exhibiting antimicrobial activity against S. mutans, S. epidermidis, or combinations thereof.

### Claim 14 (depends on 13)

The chimeric peptide of claim 13, wherein the inorganic binding domain amino acid sequence is RPRENRGRERGL (SEQ ID NO: 7) and the antimicrobial domain acid sequence is LKLLKKLLKLLKKL (SEQ ID NO: 8).

### Claim 15 (depends on 14)

The chimeric peptide of claim 14, wherein the spacer domain amino acid sequence is GSGGG (SEQ ID NO: 2).

### Claim 16 (depends on 1)

The chimeric peptide of claim 1, wherein the inorganic binding domain amino acid sequence is selected from the group consisting of: RPRENRGRERGL (SEQ ID NO: 7), GRAVRRSIRRRV (SEQ ID NO: 20), AIRGIRGIRGIR (SEQ ID NO: 21), CMLPHHGAC (SEQ ID NO: 36), RPRENRGRERF (SEQ ID NO: 40), and RPREQRGRER (SEQ ID NO: 41); the antimicrobial domain acid sequence is selected from the group consisting of: LKLLKKLLKLLKKL (SEQ ID NO: 8), ESYKRMF (SEQ ID NO: 14), ESYKHMF (SEQ ID NO: 15), ATLGVLWEGARGHT (SEQ ID NO: 18), KWKLWKKIEKWGQGIGAVLKWLTTWL (SEQ ID NO: 22), KRWWKWWRR (SEQ ID NO: 37), and KWKRWWWWR (SEQ ID NO: 39); and the spacer domain amino acid sequence is selected from the group consisting of: GGG (SEQ ID NO: 1), GSGGG (SEQ ID NO: 2); KGSVLSAD (SEQ ID NO: 23), WLMNYFWPL (SEQ ID NO: 42), YLMNYLLPY (SEQ ID NO: 43), PKSALQEL (SEQ ID NO: 44), IGVVISAV (SEQ ID NO: 45), KGSVYLLPY (SEQ ID NO: 46), and WLMNLSAD (SEQ ID NO: 47).

### Claim 17 (depends on 1)

The chimeric peptide of claim 1, wherein the inorganic binding domain amino acid sequence is that of acrylic polymer binding peptide and/or a polyurethane binding peptide, and the antimicrobial domain amino acid sequence is that of an antimicrobial domain exhibiting antimicrobial activity against S. mutans, S. epidermidis, or combinations thereof.

### Claim 18 (depends on 17)

The chimeric peptide of claim 17, wherein the inorganic binding domain amino acid sequence is selected from GRAVRRSIRRRV (SEQ ID NO: 20) and AIRGIRGIRGIR (SEQ ID NO: 21); the antimicrobial domain acid sequence is selected from LKLLKKLLKLLKKL (SEQ ID NO: 8) and KWKLWKKIEKWGQGIGAVLKWLTTWL (SEQ ID NO: 22); and the spacer domain amino acid sequence is selected from GGG (SEQ ID NO: 1), GSGGG (SEQ ID NO: 2), and KGSVLSAD (SEQ ID NO: 23).

### Claim 19 (depends on 1)

The chimeric peptide of claim 1, wherein the inorganic binding domain amino acid sequence is that of calcium phosphate binding peptide, and the antimicrobial domain amino acid sequence is that of an antimicrobial domain exhibiting antimicrobial activity against S. mutans, S. epidermidis, or combinations thereof.

### Claim 20 (depends on 19)

The chimeric peptide of claim 19, wherein the inorganic binding domain amino acid sequence is CMLPHHGAC (SEQ ID NO: 36) and the antimicrobial domain acid sequence is KRWWKWWRR (SEQ ID NO: 37).

### Claim 21 (depends on 20)

The chimeric peptide of claim 20, wherein the spacer domain amino acid sequence is GGG (SEQ ID NO: 1).

### Claim 22 (depends on 1)

The chimeric peptide of claim 1, wherein the inorganic binding domain amino acid sequence is that of zirconia binding peptide, and the antimicrobial domain amino acid sequence is that of an antimicrobial domain exhibiting antimicrobial activity against S. mutans, S. epidermidis, or combinations thereof.

### Claim 23 (depends on 22)

The chimeric peptide of claim 22, wherein the inorganic binding domain amino acid sequence is selected from RPRENRGRERF (SEQ ID NO: 40) and RPREQRGRER (SEQ ID NO: 41); the antimicrobial domain acid sequence is selected from LKLLKKLLKLLKKL (SEQ ID NO: 8) and KWKRWWWWR (SEQ ID NO: 39); and the spacer domain amino acid sequence is selected from GGG (SEQ ID NO: 1), WLMNYFWPL (SEQ ID NO: 42), YLMNYLLPY (SEQ ID NO: 43), PKSALQEL (SEQ ID NO: 44), IGVVISAV (SEQ ID NO: 45), KGSVYLLPY (SEQ ID NO: 46), and WLMNLSAD (SEQ ID NO: 47).

### Claim 24 (depends on 1)

The chimeric peptide of claim 1, wherein the inorganic binding domain amino acid sequence is RPRENRGRERGL (SEQ ID NO: 7); the antimicrobial domain acid sequence is LKLLKKLLKLLKKL (SEQ ID NO: 8); and the spacer domain amino acid sequence is selected from: WLMNYFWPL (SEQ ID NO: 42), YLMNYLLPY (SEQ ID NO: 43), PKSALQEL (SEQ ID NO: 44), and KGSVLSAD (SEQ ID NO: 23).

### Claim 25 (depends on 1)

The chimeric peptide of claim 1, wherein the inorganic binding domain amino acid sequence is RPREQRGERPRP (SEQ ID NO: 56); the antimicrobial domain acid sequence is LKLLKKLLKLLKKL (SEQ ID NO: 8); and the spacer domain amino acid sequence is selected from: GGG (SEQ ID NO: 1); GSGGG (SEQ ID NO: 2); WLMNYFWPL (SEQ ID NO: 42), YLMNYLLPY (SEQ ID NO: 43), PKSALQEL (SEQ ID NO: 44), and KGSVLSAD (SEQ ID NO: 23).

### Claim 26 (depends on 1)

The chimeric peptide of claim 1, wherein the chimeric peptide is
(SEQ ID NO: 9)
RPRENRGRERGLGGGLKLLKKLLKLLKKL;
(SEQ ID NO: 10)
RPRENRGRERGLGSGGGLKLLKKLLKLLKKL;
(SEQ ID NO: 57)
RPRENRGRERGLWLMNYFWPLLKLLKKLLKLLKKL;
(SEQ ID NO: 58)
RPRENRGRERGLYLMNYLLPYLKLLKKLLKLLKKL;
(SEQ ID NO: 59)
RPRENRGRERGLPKSALQELLKLLKKLLKLLKKL;
(SEQ ID NO: 60)
RPRENRGRERGLKGSVLSADLKLLKKLLKLLKK;
(SEQ ID NO: 61)
RPREQRGERPRPWLMNYFWPLLKLLKKLLKLLKKL;
(SEQ ID NO: 62)
RPREQRGERPRPYLMNYLLPYLKLLKKLLKLLKKL;
(SEQ ID NO: 63)
RPREQRGERPRPPKSALQELLKLLKKLLKLLKKL;
(SEQ ID NO: 64)
RPREQRGERPRPKGSVLSADLKLLKKLLKLLKK;
(SEQ ID NO: 65)
RPREQRGERPRPGGGLKLLKKLLKLLKKL;
(SEQ ID NO: 66)
RPREQRGERPRPGSGGGLKLLKKLLKLLKKL;
(SEQ ID NO: 24)
GRAVRRSIRRRVGSGGGLKLLKKLLKLLKK;
(SEQ ID NO: 25)
GRAVRRSIRRRVGSGGGKWKLWKKIEKWGQGIGAVLKWLTTWL;
(SEQ ID NO: 26)
GRAVRRSIRRRVKGSVLSADLKLLKKLLKLLKK;
(SEQ ID NO: 27)
GRAVRRSIRRRVKGSVLSADKWKLWKKIEKWGQGIGAVLKWLTTWL;
(SEQ ID NO: 28)
GRAVRRSIRRRVGGGLKLLKKLLKLLKK;
(SEQ ID NO: 29)
GRAVRRSIRRRVGGGKWKLWKKIEKWGQGIGAVLKWLTTWL;
(SEQ ID NO: 30)
AIRGIRGIRGIRGSGGGLKLLKKLLKLLKK;
(SEQ ID NO: 31)
AIRGIRGIRGIRGSGGGKWKLWKKIEKWGQGIGAVLKWLTTWL;
(SEQ ID NO: 32)
AIRGIRGIRGIRKGSVLSADLKLLKKLLKLLKK;
(SEQ ID NO: 33)
AIRGIRGIRGIRKGSVLSADKWKLWKKIEKWGQGIGAVLKWLTTWL;
(SEQ ID NO: 34)
AIRGIRGIRGIRGGGLKLLKKLLKLLKK;
(SEQ ID NO: 35)
AIRGIRGIRGIRGGGKWKLWKKIEKWGQGIGAVLKWLTTWL;
(SEQ ID NO: 38)
CMLPHHGACGGGKRWWKWWRR;
(SEQ ID NO: 48)
RPRENRGRERFIGVVISAVLKLLKKLLKLLKKL;
(SEQ ID NO: 49)
RPRENRGRERFWLMNYFWPLLKLLKKLLKLLKKL;
(SEQ ID NO: 50)
RPRENRGRERFYLMNYLLPYLKLLKKLLKLLKKL;
(SEQ ID NO: 51)
RPRENRGRERFPKSALQELLKLLKKLLKLLKKL;
(SEQ ID NO: 52)
RPRENRGRERFGGGLKLLKKLLKLLKKL;
(SEQ ID NO: 53)
RPRENRGRERFKGSVYLLPYLKLLKKLLKLLKK;
(SEQ ID NO: 54)
RPRENRGRERFWLMNLSADLKLLKKLLKLLKKL;
and
(SEQ ID NO: 55)
RPRENRGRERFKGSVLSADLKLLKKLLKLLKKL.

### Claim 27

(canceled)

### Claim 28

(canceled)

### Claim 29

(canceled)

### Claim 30

(canceled)

### Claim 31

(canceled)

### Claim 32 (depends on 1)

A coated inorganic substrate comprising a layer of the chimeric peptide of claim 1 on a surface of an inorganic substrate.

### Claim 33

(canceled)

### Claim 34 (depends on 32)

A method of making the coated inorganic substrate of claim 32, comprising contacting the inorganic substrate with a solution of the chimeric peptide.

### Claim 35

(canceled)
